Insights

Strategic Partnerships CymaBay has a history of collaborating with external partners to accelerate capabilities, such as digital pathology workflow transformation with Glencoe Software and recruitment process optimization with Skills Alliance, presenting opportunities for co-development, CRO/CSO partnerships, and technology-enabled trial enhancements.

Clinical Pipeline Focus With Seladelpar targeting primary biliary cholangitis and an ongoing pipeline for liver and other chronic diseases, sales conversations can emphasize compound support, access programs, and potential companion diagnostics or tailored patient access strategies for orphan or niche liver indications.

Acquisition Proximity Frequent market chatter and merger activity involving CymaBay suggest a transitional window for outbound discussions around licensing, acquisition-friendly partnerships, and strategic alliances that align with a potential buyer’s portfolio strategy.

Financial and Scale Signals Revenue in the mid tens of millions and substantial funding indicate readiness for scaled collaborations, clinical development partnerships, and joint ventures to advance late-stage development, manufacturing licenses, or commercialization support.

Technology Enablement Adoption of enterprise tools (SAS, NetSuite, OneTrust, ADP, Smartsheet) and digital workflow initiatives highlight openness to technology-enabled service models, suggesting offerings in data analytics, regulatory/compliance support, and trial operations optimization.

Similar companies to CymaBay Therapeutics

CymaBay Therapeutics Tech Stack

CymaBay Therapeutics uses 8 technology products and services including SAS, Sitecore, OneTrust, and more. Explore CymaBay Therapeutics's tech stack below.

Media & News

CymaBay Therapeutics's Email Address Formats

CymaBay Therapeutics uses at least 4 email formats:
CymaBay Therapeutics Email FormatsExamplePercentage
FLast@cymabay.comJDoe@cymabay.com
96%
FiLast@cymabay.comJoDoe@cymabay.com
2%
FirstMiddleLas@cymabay.comJohnMichaelDoe@cymabay.com
1%
FirLast@cymabay.comJohDoe@cymabay.com
1%

Frequently Asked Questions

What is CymaBay Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact CymaBay Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CymaBay Therapeutics's stock symbol?

Minus sign iconPlus sign icon
CymaBay Therapeutics is a publicly traded company; the company's stock symbol is CBAY.

What is CymaBay Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
CymaBay Therapeutics's official website is cymabay.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does CymaBay Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, CymaBay Therapeutics's annual revenue is estimated to be $25M - $50M.

What is CymaBay Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
CymaBay Therapeutics's SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does CymaBay Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, CymaBay Therapeutics has approximately 22 employees across 1 continents, including North America. Key team members include Chief Medical Officer: M. K., Corporate Controller: A. P. and Director Biostatistics: S. Z. Explore CymaBay Therapeutics's employee directory with LeadIQ.

What industry does CymaBay Therapeutics belong to?

Minus sign iconPlus sign icon
CymaBay Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does CymaBay Therapeutics use?

Minus sign iconPlus sign icon
CymaBay Therapeutics's tech stack includes SAS, Sitecore, OneTrust, NetSuite, ADP, Hootsuite, Smartsheet and Adobe Creative Suite.

What is CymaBay Therapeutics's email format?

Minus sign iconPlus sign icon
CymaBay Therapeutics's email format typically follows the pattern of FLast@cymabay.com. Find more CymaBay Therapeutics email formats with LeadIQ.

How much funding has CymaBay Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, CymaBay Therapeutics has raised $854M in funding. The last funding round occurred on Oct 11, 2023 for $259M.
CymaBay Therapeutics logo

CymaBay Therapeutics

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

CymaBay Therapeutics is a clinical-stage biopharmaceutical company pursuing therapies for liver diseases and other chronic conditions with limited treatment options. The company is based in Newark, California. Its lead candidate, Seladelpar, is an oral agent targeting the PPARδ pathway and is being developed for primary biliary cholangitis, an autoimmune liver disease.

Beyond Seladelpar, CymaBay is advancing additional investigational products and lead candidates for liver and other chronic diseases. In December 2025, the company announced a collaboration with Glencoe Software to digitally transform a pathology review workflow, a step aimed at supporting an NDA-enabling clinical trial ahead of schedule.

Section iconCompany Overview

Phone number
SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
Stock Symbol
CBAY
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
11-50

Section iconFunding & Financials

  • $854M

    CymaBay Therapeutics has raised a total of $854M of funding over 16 rounds. Their latest funding round was raised on Oct 11, 2023 in the amount of $259M as a Post IPO Equity.

  • $25M - $50M

    CymaBay Therapeutics's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.